Financial Review: Jushi (JUSHF) vs. Its Peers

Jushi (OTCMKTS:JUSHF) is one of 53 publicly-traded companies in the “Medicinals & botanicals” industry, but how does it contrast to its competitors? We will compare Jushi to similar companies based on the strength of its risk, institutional ownership, earnings, valuation, profitability, dividends and analyst recommendations.

Profitability

This table compares Jushi and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jushi	-24.16%	-320.66%	-10.31%
Jushi Competitors	-45.95%	-62.18%	-9.03%

Institutional & Insider Ownership

21.7% of Jushi shares are held by institutional investors. Comparatively, 14.3% of shares of all “Medicinals & botanicals” companies are held by institutional investors. 21.0% of Jushi shares are held by insiders. Comparatively, 21.5% of shares of all “Medicinals & botanicals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Jushi has a beta of -0.16, indicating that its stock price is 116% less volatile than the S&P 500. Comparatively, Jushi’s competitors have a beta of 1.40, indicating that their average stock price is 40% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Jushi and its competitors, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jushi	0	2	0	0	2.00
Jushi Competitors	203	531	843	66	2.47

As a group, “Medicinals & botanicals” companies have a potential upside of 70.25%. Given Jushi’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Jushi has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Jushi and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Jushi	$269.45 million	-$65.10 million	-1.93
Jushi Competitors	$323.20 million	-$162.62 million	-10.00

Jushi’s competitors have higher revenue, but lower earnings than Jushi. Jushi is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Summary

Jushi competitors beat Jushi on 9 of the 13 factors compared.

About Jushi

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of medical and adult-use products. It focuses on building a portfolio of cannabis assets in various jurisdictions in Pennsylvania, Virginia, Ohio, Illinois, California, Nevada, and Massachusetts. The company also offers hemp-based CBD products, including cannabis dry flower, vaporizer forms of cannabis, edibles, cannabis oil in capsules, tinctures, cannabis in topical products, and other cannabis products, as well as vape cartridges, disposables, and concentrates under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. In addition, it operates medical cannabis dispensaries under the BEYOND/HELLO, Nature's Remedy, and NuLeaf brands. The company is headquartered in Boca Raton, Florida.